A Study of AZD0486 for B-Cell Non-Hodgkin Lymphoma
Phase 1
317
about 7.1 years
18–130
10 sites in FL, KY, NC +6
About this study
This trial is testing the safety and how well AZD0486 works in people with B-cell non-Hodgkin lymphoma. AZD0486 is a type of drug given through an IV infusion.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive AZD0486 IV
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
infusion
Primary: Apparent terminal half-life (t1/2) of AZD0486, Incidence of subjects with Dose-limiting toxicities (DLT), Incidence of subjects with adverse events (AEs) and/or serious adverse events (SAEs), Maximum Observed Serum Concentration of AZD0486 (Cmax)
Secondary: Anti-Lymphoma Activity by Duration of Objective Response (DOR), Anti-Lymphoma Activity by Objective Response Rate (ORR), Anti-Lymphoma Activity by Progression-Free Survival (PFS)
Oncology